12422 related articles for article (PubMed ID: 10958054)
1. Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies.
Fonsatti E; Altomonte M; Coral S; De Nardo C; Lamaj E; Sigalotti L; Natali PG; Maio M
Clin Ter; 2000; 151(3):187-93. PubMed ID: 10958054
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement.
Coral S; Fonsatti E; Sigalotti L; De Nardo C; Visintin A; Nardi G; Colizzi F; Colombo MP; Romano G; Altomonte M; Maio M
J Cell Physiol; 2000 Dec; 185(3):317-23. PubMed ID: 11056001
[TBL] [Abstract][Full Text] [Related]
3. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.
Brasoveanu LI; Fonsatti E; Visintin A; Pavlovic M; Cattarossi I; Colizzi F; Gasparollo A; Coral S; Horejsi V; Altomonte M; Maio M
J Clin Invest; 1997 Sep; 100(5):1248-55. PubMed ID: 9276743
[TBL] [Abstract][Full Text] [Related]
4. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.
De Nardo C; Fonsatti E; Sigalotti L; Calabrò L; Colizzi F; Cortini E; Coral S; Altomonte M; Maio M
J Cell Physiol; 2002 Feb; 190(2):200-6. PubMed ID: 11807824
[TBL] [Abstract][Full Text] [Related]
5. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).
Maio M; Brasoveanu LI; Coral S; Sigalotti L; Lamaj E; Gasparollo A; Visintin A; Altomonte M; Fonsatti E
Int J Oncol; 1998 Aug; 13(2):305-18. PubMed ID: 9664126
[TBL] [Abstract][Full Text] [Related]
6. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic immunomodulation of hematopoietic malignancies.
Gattei V; Fonsatti E; Sigalotti L; Degan M; Di Giacomo AM; Altomonte M; Calabrò L; Maio M
Semin Oncol; 2005 Oct; 32(5):503-10. PubMed ID: 16210091
[TBL] [Abstract][Full Text] [Related]
8. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
10. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
11. Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
Fonsatti E; Di Giacomo AM; Maio M
J Transl Med; 2004 Jun; 2(1):21. PubMed ID: 15219237
[TBL] [Abstract][Full Text] [Related]
12. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Altomonte M; Fonsatti E; Visintin A; Maio M
Oncogene; 2003 Sep; 22(42):6564-9. PubMed ID: 14528281
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy.
Sigalotti L; Coral S; Fratta E; Lamaj E; Danielli R; Di Giacomo AM; Altomonte M; Maio M
Semin Oncol; 2005 Oct; 32(5):473-8. PubMed ID: 16210088
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy.
Baxevanis CN; Perez SA; Papamichail M
Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
[TBL] [Abstract][Full Text] [Related]
16. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
19. Complement as effector system in cancer immunotherapy.
Macor P; Tedesco F
Immunol Lett; 2007 Jul; 111(1):6-13. PubMed ID: 17572509
[TBL] [Abstract][Full Text] [Related]
20. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue.
Harrower TP; Richards A; Cruz G; Copeman L; Dunnett SB; Barker RA
Xenotransplantation; 2004 Jan; 11(1):60-71. PubMed ID: 14962294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
